BiotechTube

Camrelizumab + Apatinib

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Intrahepatic Cholangiocarcinoma

Conditions

Intrahepatic Cholangiocarcinoma

Trial Timeline

Aug 1, 2020 → Jul 1, 2025

NCT ID
NCT04454905

About Camrelizumab + Apatinib

Camrelizumab + Apatinib is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Intrahepatic Cholangiocarcinoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT04454905. Target conditions include Intrahepatic Cholangiocarcinoma.

What happened to similar drugs?

0 of 4 similar drugs in Intrahepatic Cholangiocarcinoma were approved

Approved (0) Terminated (1) Active (3)
🔄A4250 (odevixibat)IpsenPhase 3
🔄MaralixibatMirum PharmaceuticalsPhase 3
🔄MaralixibatMirum PharmaceuticalsPhase 3
❌Maralixibat + PlaceboMirum PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04454905Phase 2UNKNOWN

Competing Products

20 competing products in Intrahepatic Cholangiocarcinoma

See all competitors
ProductCompanyStageHype Score
ApatinibJiangsu Hengrui MedicinePhase 2
31
Apatinib and Adebrelimab in Combination With chemotherapyJiangsu Hengrui MedicinePhase 2
42
ApatinibJiangsu Hengrui MedicinePhase 2
35
FamitinibJiangsu Hengrui MedicinePhase 2
27
Durvalumab + SNDX-6352AstraZenecaPhase 2
35
Durvalumab + TremelimumabAstraZenecaPhase 2
39
Pemigatinib + DurvalumabAstraZenecaPhase 2
42
Durvalumab + Gemcitabine + CisplatinAstraZenecaPhase 2
42
PemigatinibIncytePhase 2
24
A4250 (odevixibat)IpsenPhase 3
37
OdevixibatIpsenPre-clinical
23
CGT4859Cogent BiosciencesPhase 1/2
36
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
32
MaralixibatMirum PharmaceuticalsPhase 3
37
MaralixibatMirum PharmaceuticalsPhase 2
39
MaralixibatMirum PharmaceuticalsPhase 2
32
Volixibat + PlaceboMirum PharmaceuticalsPhase 2
24
MaralixibatMirum PharmaceuticalsPhase 3
37
Maralixibat + PlaceboMirum PharmaceuticalsPhase 3
29
HMPL-453 + RabeprazoleHUTCHMEDPhase 1
23